Publicaciones (46) Publicaciones de José Manuel Aramendía Beitia

2024

  1. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)

    International Journal of Gynecological Cancer, Vol. 34, Núm. 6, pp. 942-945

  2. Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

    Clinical and Translational Oncology

2023

  1. A pharmacometrics model to define docetaxel target in early breast cancer

    British Journal of Clinical Pharmacology, Vol. 89, Núm. 2, pp. 727-736

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

2021

  1. Intraoperative electron beam radiotherapy and perioperative high-dose-rate brachytherapy in previously irradiated oligorecurrent gynecological cancer: clinical outcome analysis

    Clinical and Translational Oncology, Vol. 23, Núm. 9, pp. 1934-1941

  2. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2020

  1. Complete cytoreductive surgery, the key factor for survival in advanced ovarian cancer. Experience of an intermediate volume hospital

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 6, pp. 906-912

  2. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer

    European Journal of Gynaecological Oncology, Vol. 41, Núm. 4, pp. 523-530

2019

  1. Dietary inflammatory index and incidence of breast cancer in the SUN project

    Clinical Nutrition, Vol. 38, Núm. 5, pp. 2259-2268

2018

  1. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience

    Breast Journal, Vol. 24, Núm. 4, pp. 473-479

  2. Erratum: Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial (Brachytherapy (2018) 17(5) (734–741), (S1538472118300898) (10.1016/j.brachy.2018.04.007))

    Brachytherapy

  3. Perioperative high-dose-rate brachytherapy in locally advanced and recurrent gynecological cancer: Final results of a Phase II trial

    Brachytherapy, Vol. 17, Núm. 5, pp. 734-741

2016

  1. Long-Term Results of a Phase II Trial of Concomitant Cisplatin-Paclitaxel Chemoradiation in Locally Advanced Cervical Cancer

    International Journal of Gynecological Cancer, Vol. 26, Núm. 6, pp. 1162-1168

  2. Multicatheter breast implant during breast conservative surgery: Novel approach to deliver accelerated partial breast irradiation

    Brachytherapy, Vol. 15, Núm. 4, pp. 485-494

  3. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. 37th Annual San Antonio Breast Cancer Symposium. Summary of the most important translational and clinical contributions

    Revista de Senologia y Patologia Mamaria

  2. Safety and efficacy of temsirolimus under compassionate use in heavily pretreated patients with poor-prognosis solid tumors

    Minerva Chirurgica

  3. Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity

    Annals of Allergy, Asthma and Immunology, Vol. 114, Núm. 6, pp. 534-535

2013

  1. Neurological and cytological response as potential early predictors of time-to-progression and overall survival in patients with leptomeningeal carcinomatosis treated with intrathecal liposomal cytarabine: A retrospective cohort study

    Journal of Neuro-Oncology

2011

  1. A novel mutation in BRCA1 linked to breast and ovarian cancer and a genotype-phenotype correlation

    Oncology Letters, Vol. 2, Núm. 5, pp. 807-809